Welcome to LookChem.com Sign In|Join Free

CAS

  • or
ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9& is an organic compound that serves as an important intermediate in the synthesis of various chemical compounds. It is characterized by its unique structure and properties, making it a valuable component in the development of pharmaceuticals and other chemical products.

774-05-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 774-05-0 Structure
  • Basic information

    1. Product Name: ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9&
    2. Synonyms: ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9&;ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE, 97 %;Ethyl 2-oxocycloheptanecarboxylate;2-Oxo-1-Cyclooctanecarboxylate Methyl ester;ethyl 2-oxocycloheptane-1-carboxylate;_x005f\rEthyl 2-Oxocycloheptanecarboxylate
    3. CAS NO:774-05-0
    4. Molecular Formula: C10H16O3
    5. Molecular Weight: 198.25882
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 774-05-0.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 85-87 °C0.1 mm Hg(lit.)
    3. Flash Point: >230 °F
    4. Appearance: /
    5. Density: 1.04 g/mL at 25 °C(lit.)
    6. Refractive Index: n20/D 1.483(lit.)
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 12.06±0.20(Predicted)
    10. CAS DataBase Reference: ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9&(CAS DataBase Reference)
    11. NIST Chemistry Reference: ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9&(774-05-0)
    12. EPA Substance Registry System: ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9&(774-05-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 774-05-0(Hazardous Substances Data)

774-05-0 Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-OXO-1-CYCLOOCTANECARBOXYLATE 9& is used as a key intermediate in the synthesis of fused tricyclic coumarin sulfonate derivatives. These derivatives exhibit antiproliferative activity against a panel of 57 human cancer cell lines, making them potential candidates for the development of new anticancer drugs.

Synthesis Reference(s)

The Journal of Organic Chemistry, 42, p. 459, 1977 DOI: 10.1021/jo00423a015

Check Digit Verification of cas no

The CAS Registry Mumber 774-05-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,7 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 774-05:
(5*7)+(4*7)+(3*4)+(2*0)+(1*5)=80
80 % 10 = 0
So 774-05-0 is a valid CAS Registry Number.

774-05-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 2-oxo-cycloheptanecarboxylate

1.2 Other means of identification

Product number -
Other names ethyl 2-oxocycloheptane-1-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:774-05-0 SDS

774-05-0Synthetic route

Diethyl carbonate
105-58-8

Diethyl carbonate

cycloheptanone

cycloheptanone

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
Stage #1: Diethyl carbonate With sodium hydride In toluene; mineral oil at 20 - 100℃; Inert atmosphere;
Stage #2: cycloheptanone In toluene; mineral oil at 100℃; for 4.5h; Inert atmosphere;
98%
With sodium hydride In benzene Reflux;90%
With sodium hydride In mineral oil; benzene Reflux;90%
1-hydroxy-1-ethoxycarbonyl-diazomethylcyclohexane
27262-60-8

1-hydroxy-1-ethoxycarbonyl-diazomethylcyclohexane

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With dirhodium tetraacetate In dichloromethane; acetonitrile for 1.75h;97%
diazoacetic acid ethyl ester
623-73-4

diazoacetic acid ethyl ester

4-(4-t-butyldimethylsilyloxyphenyl)cyclohexanone

4-(4-t-butyldimethylsilyloxyphenyl)cyclohexanone

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
Stage #1: 4-(4-t-butyldimethylsilyloxyphenyl)cyclohexanone With boron trifluoride diethyl etherate In diethyl ether for 0.333333h; Inert atmosphere;
Stage #2: diazoacetic acid ethyl ester In diethyl ether at 20℃; for 12h; Inert atmosphere;
81%
diazoacetic acid ethyl ester
623-73-4

diazoacetic acid ethyl ester

cyclohexanone
108-94-1

cyclohexanone

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With boron trifluoride diethyl etherate In diethyl ether at 0 - 20℃; for 3.25h; Inert atmosphere;76%
With boron trifluoride diethyl etherate In diethyl ether for 1h; Ambient temperature;74%
With aluminium trichloride In diethyl ether
(i) nBuLi, (ii) HCl; Multistep reaction;
With antimonypentachloride In dichloromethane
oxalic acid diethyl ester
95-92-1

oxalic acid diethyl ester

cycloheptanone
502-42-1

cycloheptanone

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With sodium ethanolate In ethanol at -5 - 25℃; for 5h;50%
With ethanol; sodium ethanolate Erhitzen des Reaktionsprodukts unter Zusatz von Eisen und Glaspulver;
With ethanol; sodium ethanolate Erhitzen des Reaktionsprodukts;
With ethanol; sodium ethanolate Erhitzen des Reaktionsprodukts unter Zusatz von Borsaeure;
diethyl suberate
2050-23-9

diethyl suberate

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With sodium at 120 - 140℃;
chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

4-(1-cyclohepten-1-yl)morpholine
7182-08-3

4-(1-cyclohepten-1-yl)morpholine

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
(i) benzene, (ii) aq. HCl; Multistep reaction;
ethanol
64-17-5

ethanol

((1R,7R)-8,8-Dichloro-bicyclo[5.1.0]oct-1-yloxy)-trimethyl-silane
124356-14-5

((1R,7R)-8,8-Dichloro-bicyclo[5.1.0]oct-1-yloxy)-trimethyl-silane

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With ferric nitrate (electrolysis);
diethyl suberate
2050-23-9

diethyl suberate

sodium

sodium

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
at 120 - 140℃;
(cyclohept-1-en-1-yloxy)(trimethyl)silane
22081-48-7

(cyclohept-1-en-1-yloxy)(trimethyl)silane

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH, 2NEt3>Cl
2: Fe(NO3)3 / (electrolysis)
View Scheme
chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

cycloheptanone
502-42-1

cycloheptanone

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

Conditions
ConditionsYield
With cetyltrimethylammonium chloride; calcium carbonate; calcium oxide In 1,4-dioxane at 25℃; for 3h; Sonication;95 %Chromat.
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

2-(3,4-dimethoxyphenyl)-ethylamine
120-20-7

2-(3,4-dimethoxyphenyl)-ethylamine

2-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-cyclohept-1-enecarboxylic acid ethyl ester
130655-37-7

2-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-cyclohept-1-enecarboxylic acid ethyl ester

Conditions
ConditionsYield
In ethanol at 100℃;100%
In ethanol at 100℃; for 2h;
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

propynoic acid ethyl ester
623-47-2

propynoic acid ethyl ester

1-((E)-2-Ethoxycarbonyl-vinyl)-2-oxo-cycloheptanecarboxylic acid ethyl ester

1-((E)-2-Ethoxycarbonyl-vinyl)-2-oxo-cycloheptanecarboxylic acid ethyl ester

Conditions
ConditionsYield
With potassium carbonate In acetone at 20℃; for 72h;99%
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

N,N-bis(ethoxymethyl)benzylamine
55686-29-8

N,N-bis(ethoxymethyl)benzylamine

C19H25NO3
1260180-26-4

C19H25NO3

Conditions
ConditionsYield
With Methyltrichlorosilane In acetonitrile double-Mannich reaction;99%
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

ethyl acrylate
140-88-5

ethyl acrylate

3-(1-ethoxycarbonyl-2-oxo-cycloheptyl)-propionic acid ethyl ester
791-33-3

3-(1-ethoxycarbonyl-2-oxo-cycloheptyl)-propionic acid ethyl ester

Conditions
ConditionsYield
With trifluoroacetic acid at 20℃; for 10h; Addition; Michael addition;97%
With 1,8-diazabicyclo[5.4.0]undec-7-ene In ethanol at 20℃; for 0.5h; Michael addition;91%
With potassium tert-butylate
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

benzoic acid hydrazide
613-94-5

benzoic acid hydrazide

2-(Benzoyl-hydrazono)-cycloheptanecarboxylic acid ethyl ester

2-(Benzoyl-hydrazono)-cycloheptanecarboxylic acid ethyl ester

Conditions
ConditionsYield
In isopropyl alcohol for 0.5h; Heating;96%
chloro-trimethyl-silane
75-77-4

chloro-trimethyl-silane

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

3-<(ethoxy)(trimethylsiloxy)methylidene>-2-(trimethylsiloxy)cyclohept-1-ene
227943-23-9

3-<(ethoxy)(trimethylsiloxy)methylidene>-2-(trimethylsiloxy)cyclohept-1-ene

Conditions
ConditionsYield
Stage #1: ethyl cycloheptanone-2-carboxylate With lithium diisopropyl amide In tetrahydrofuran at 0℃; for 1.5h; deprotonation;
Stage #2: chloro-trimethyl-silane In tetrahydrofuran at 0℃; for 2h; silylation; Further stages.;
95%
With diisopropylamine; lithium diisopropyl amide In tetrahydrofuran; hexane at 0℃; for 3h;95%
With lithium diisopropyl amide 1.) THF, 0 deg C, 1.5 h, 2.) THF, 0 deg C, 1 h; Yield given; Multistep reaction;
Stage #1: ethyl cycloheptanone-2-carboxylate With lithium diisopropyl amide In tetrahydrofuran at 0℃; for 1.5h; deprotonation;
Stage #2: chloro-trimethyl-silane In tetrahydrofuran at 0℃; for 2h; silylation;
ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

phenylacetylene
536-74-3

phenylacetylene

1-ethyl 3-methyl (1Z)-4-oxo-2-phenylcyclonon-1-ene-1-carboxylate

1-ethyl 3-methyl (1Z)-4-oxo-2-phenylcyclonon-1-ene-1-carboxylate

Conditions
ConditionsYield
With bromopentacarbonylmanganese(I) at 80℃; for 24h; neat (no solvent);93%
With Benzyl isocyanide; bromotricarbonyl(tetrahydrofuran)rhenium(I) dimer at 40℃; for 24h;87%
2-aminopyridine
504-29-0

2-aminopyridine

ethyl cycloheptanone-2-carboxylate
774-05-0

ethyl cycloheptanone-2-carboxylate

2,3-cycloheptapyrido<1,2-a>pyrimidinone
70026-42-5

2,3-cycloheptapyrido<1,2-a>pyrimidinone

Conditions
ConditionsYield
With bismuth(III) chloride at 100℃; for 3h; Green chemistry;92%

774-05-0Relevant articles and documents

Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs)

Sampathi Perera, K.L.Iresha,Hanson, Alicia M.,Lindeman, Sergey,Imhoff, Andrea,Lu, Xingyun,Sem, Daniel S.,Donaldson, William A.

, p. 791 - 804 (2018)

A short and efficient route to 4-(4-hydroxyphenyl)cycloheptanemethanol was developed, which resulted in the preparation of a mixture of 4 stereoisomers. The stereoisomers were separated by preparative HPLC, and two of the stereoisomers identified by X-ray crystallography. The stereoisomers, as well as a small family of 4-cycloheptylphenol derivatives, were evaluated as estrogen receptor-beta agonists. The lead compound, 4-(4-hydroxyphenyl)cycloheptanemethanol was selective for activating ER relative to seven other nuclear hormone receptors, with 300-fold selectivity for the β over α isoform and with EC50 of 30–50 nM in cell-based and direct binding assays.

Electrochemical Difunctionalization of Terminal Alkynes: Access to 1,4-Dicarbonyl Compounds

Chen, Siyu,He, Haoyu,Hu, Jiayu,Hu, Jingcheng,Jiao, Ying,Lei, Aiwen,Liu, Xue,Ma, Rui,Wang, Hongfei,Xu, Zhexi,Zeng, Li

supporting information, (2022/01/04)

1,4-Dicarbonyl compounds are versatile scaffolds for the heterocycle synthesis, including the Paal-Knorr reaction. Herein, a feasible electrosynthesis method to access 1,4-dicarbonyl compounds has been developed from simple alkynes and 1,3-dicarbonyl compounds. When the undivided cell is combined with the constant current mode, aryl alkynes containing numerous medicinal motifs with 1,3-dicarbonyl esters or ketones react smoothly. External oxidant and catalyst-free conditions conform to the requirements of green synthesis.

Enantioselective α-Amination of Acyclic 1,3-Dicarbonyls Catalyzed by N-Heterocyclic Carbene

Santra, Surojit,Maji, Ujjwal,Guin, Joyram

supporting information, p. 468 - 473 (2020/02/04)

Herein, we describe a method for the catalytic enantioselective α-amination of α-substituted acyclic 1,3-ketoamides and 1,3-amidoesters that affords the products possessing N-substituted quaternary stereocenters with a chiral N-heterocyclic carbene (NHC). The reaction is based on the utilization of an intrinsic Br?nsted base characteristic of NHC that enables the catalytic formation of a chiral ion pair comprising the enolate and the azolium ion. A series of challenging open-chain α-substituted 1,3-dicarbonyls are aminated via this method with ee's of ≤99%.

Substituted pyrazoloheptylcyclo-5-formamide compound as well as preparation method and application thereof

-

Paragraph 0042-0044, (2020/09/09)

The invention discloses a substituted pyrazoloheptylcyclo-5-formamide compound as well as a preparation method and application of the substituted pyrazoloheptylcyclo-5-formamide compound. The structural formula of the substituted pyrazoloheptylcyclo-5-formamide compound is shown as the following formula I (See the specification), wherein in the formula I, n is an integer from 1 to 3, R1 is selected from hydrogen, a phenyl group, a substituted phenyl group, a C1-C4 alkoxy group, a halogenated C1-C4 alkoxy group, a C1-C4 alkyl sulfonyl group, a halogenated C1-C4 alkyl sulfonyl group, a C1-C4 alkyl carbonyl group, a halogenated C1-C4 alkyl carbonyl group, a C1-C4 alkoxy carbonyl group and a halogenated C1-C4 alkoxy carbonyl group, the substituted phenyl group contains one or more substituentgroups, and the substituent group is selected from at least one of halogen, amino, hydroxyl, nitro, cyano, C1-C4 alkyl and C1-C4 alkoxy. The compound is prepared through an amide condensation reaction, and the preparation method is simple. The pyrazoloheptylcyclo-5-formamide compound has an obvious regulation effect on the growth and development of agricultural pests, the pests have the symptoms of individual reduction, epidermis relaxation and development deformity until the pests die finally, and the pyrazoloheptylcyclo-5-formamide compound can be applied to agriculture as an insecticide.

From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors

Massari, Serena,Corona, Angela,Distinto, Simona,Desantis, Jenny,Caredda, Alessia,Sabatini, Stefano,Manfroni, Giuseppe,Felicetti, Tommaso,Cecchetti, Violetta,Pannecouque, Christophe,Maccioni, Elias,Tramontano, Enzo,Tabarrini, Oriana

, p. 55 - 74 (2018/10/31)

The paper focussed on a step-by-step structural modification of a cycloheptathiophene-3-carboxamide derivative recently identified by us as reverse transcriptase (RT)-associated ribonuclease H (RNase H) inhibitor. In particular, its conversion to a 2-aryl-cycloheptathienoozaxinone derivative and the successive thorough exploration of both 2-aromatic and cycloheptathieno moieties led to identify oxazinone-based compounds as new anti-RNase H chemotypes. The presence of the catechol moiety at the C-2 position of the scaffold emerged as critical to achieve potent anti-RNase H activity, which also encompassed anti-RNA dependent DNA polymerase (RDDP) activity for the tricyclic derivatives. Benzothienooxazinone derivative 22 resulted the most potent dual inhibitor exhibiting IC50s of 0.53 and 2.90 μM against the RNase H and RDDP functions. Mutagenesis and docking studies suggested that compound 22 binds two allosteric pockets within the RT, one located between the RNase H active site and the primer grip region and the other close to the DNA polymerase catalytic centre.

Does the Exception Prove the Rule? A Comparative Study of Supramolecular Synthons in a Series of Lactam Esters

Weck,Nauha,Gruber

, p. 2899 - 2911 (2019/05/10)

In this paper a series of simple lactam esters and carboxylic acids is studied with respect to their overall conformation and hydrogen bonding patterns. In total, eight lactams featuring Nα-substitution have been synthesized. Additionally, the molecular structures of related lactam esters have been considered. The length of the amide bonds does not seem to be majorly influenced by different substituents unless the electron withdrawing N-Boc-protection group is introduced, resulting in a higher susceptibility toward hydrolytic ring opening. As known from other lactams, the Nα ester moiety of the title compounds can be in an axial or equatorial conformation. Smaller ester groups were found to prefer equatorial positions, while larger ones occupy axial sites. N-substitution seems to promote axial conformations of the respective Nα group, with enantholactams being the only studied exception. In addition to the two common amide packing motifs, i.e., the R2 2 (8) amide dimer (NH···O/NH···O) and the C(4) amide chain, a third graph-set was found: the R2 2(8) NH···O/CH···O=C heterodimer. In general, there seems to be a tendency for medium-sized lactams as well as lactams with small esters to form R2 2 (8) amide dimers. Larger esters and enantholactam esters lead to C(4) amide chains. In this respect the formation of R2 2(8) N - H···O/C-H···O=C heterodimers should be seen as a remarkable exception.

Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation

He, Qi,Liu, Jing,Lan, Jin-Shuai,Ding, Jiaoli,Sun, Yongbing,Fang, Yuanying,Jiang, Neng,Yang, Zunhua,Sun, Liyuan,Jin, Yi,Xie, Sai-Sai

supporting information, p. 512 - 528 (2018/09/29)

A series of new coumarin-dithiocarbamate hybrids were designed and synthesized as multitarget agents for the treatment of Alzheimer's disease. Most of them showed potent and clearly selective inhibition towards AChE and MAO-B. Among these compounds, compound 8f demonstrated the most potent inhibition to AChE with IC50 values of 0.0068 μM and 0.0089 μM for eeAChE and hAChE, respectively. Compound 8g was identified as the most potent inhibitor to hMAO-B, and it is also a good and balanced inhibitor to both hAChE and hMAO-B (0.114 μM for hAChE; 0.101 μM for hMAO-B). Kinetic and molecular modeling studies revealed that 8g was a dual binding site inhibitor for AChE and a competitive inhibitor for MAO-B. Further studies indicated that 8g could penetrate the BBB and exhibit no toxicity on SH-SY5Y neuroblastoma cells. More importantly, 8g did not display any acute toxicity in mice at doses up to 2500 mg/kg and could reverse the cognitive dysfunction of scopolamine-induced AD mice. Overall, these results highlighted 8g as a potential multitarget agent for AD treatment and offered a starting point for design of new multitarget AChE/MAO-B inhibitors based on dithiocarbamate scaffold.

A new series of cycloalkane-fused coumarin sulfonates: Synthesis and in vitro antiproliferative screening

El-Gamal, Mohammed I.,Baek, Daejin,Oh, Chang-Hyun

, p. 184 - 191 (2016/02/26)

In this paper, we report the synthesis of 14 new cycloalkane-fused tricyclic coumarin sulfonate derivatives. They were examined for in vitro anticancer activity against NCI-57 cancer cell line panel of nine different cancer types. Among all the target analogs, compounds 1c, 1e, and 1n showed the highest activities. Compound 1e exerted the highest percentage growth inhibition (91.91%) against SNB-75 CNS cancer cell line at 10 μM concentration and was more active than carmustineagainst this cell line. Compound 1c also showed strong activity against HT29 colon, ACHN renal, and PC-3 prostate cancer cell lines. Furthermore, compound 1n was selective toward the HT29 colon cancer cell line. Compounds 1c, 1e, and 1n showed superior selectivity against cancer cell lines compared to the noncancerous RAW 264.7 macrophages. The in silico predictions estimate the oral bioavailability, which is in compliance with Lipinski's rule of five.

Synthesis of New Tricyclic and Tetracyclic Fused Coumarin Sulfonate Derivatives and Their Inhibitory Effects on LPS-Induced Nitric Oxide and PGE2 Productions in RAW 264.7 Macrophages: Part 2

El-Gamal, Mohammed I.,Lee, Woo-Seok,Shin, Ji-Sun,Oh, Chang-Hyun,Lee, Kyung-Tae,Choi, Jungseung,Myoung, Nohsun,Baek, Daejin

, p. 853 - 863 (2016/11/09)

The synthesis of a new series of 21 fused coumarin derivatives is described, and the biological evaluation of their in vitro antiinflammatory effects as inhibitors of lipopolysaccharide (LPS)-induced nitric oxide (NO) and prostaglandin E2 (PGE2) production in RAW 264.7 macrophages. The target compounds 1a–u were first tested for cytotoxicity to determine a non-toxic concentration for antiinflammatory screening, so that the inhibitory effects against NO and PGE2 production would not be caused by cytotoxicity. Compounds 1f and 1p were the most active PGE2 inhibitors with IC50 values of 0.89 and 0.95 μM, respectively. Western blot and cell-free COX-2 screening showed that their effects were due to inhibition of both COX-2 protein expression and COX-2 enzyme activity. Their IC50 values against the COX-2 enzyme were 0.67 and 0.85 μM, respectively, which is more potent than etoricoxib. The selectivity indexes of compounds 1f and 1p against COX-2 compared to COX-1 were 41.1 and 42.5, respectively. Compound 1f showed strong inhibitory effects at 5 μM concentration on COX-2 mRNA expression in LPS-induced RAW 264.7 macrophages. Moreover, the tricyclic compounds 1l and 1n as well as the tetracyclic analog 1u were the most potent NO inhibitors, with one-digit micromolar IC50 values. They showed dose-dependent inhibition of inducible nitric oxide synthase (iNOS) protein expression. The tetracyclic derivative 1u was the most potent inhibitor of NO production. It also exhibited a strong inhibitory effect on iNOS mRNA expression in LPS-induced RAW 264.7 macrophages.

Ethyl Lithiodiazoacetate: Extremely Unstable Intermediate Handled Efficiently in Flow

Müller, Simon T. R.,Hokamp, Tobias,Ehrmann, Svenja,Hellier, Paul,Wirth, Thomas

supporting information, p. 11940 - 11942 (2016/08/16)

Ethyl diazoacetate (EDA) is one of the most prominent diazo reagents. It is frequently used in metal–carbene-type reactions. However, EDA can also be used as a nucleophile under base catalysis. Whilst the addition of EDA to aldehydes can be performed using organic bases, the addition of EDA to other carbonyl electrophiles requires the use of organometallics such as lithium diisopropylamide (LDA). The generated ethyl lithiodiazoacetate is highly reactive and decomposes rapidly, even at low temperatures. Herein, we report a continuous flow protocol that overcomes the problems associated with the instantaneous decomposition of ethyl lithiodiazoacetate. The addition of ethyl lithiodiazoacetate to ketones provides direct access to tertiary diazoalcohols in good yields.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 774-05-0